Actively Recruiting
Early-Phase 1 Study Evaluating Safety and Effectiveness of ZZSW-01 Injection for Adults With Relapsed or Refractory B-cell Cancers
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-11-21
6
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary efficacy of ZZSW-01 injection in patients with relapsed or refractory B-cell blood cancers. This early-phase 1, single-center, single-arm, open-label study focuses on patients who have not responded to previous treatments. ZZSW-01 uses an extracellular vesicle that carries CD19 CAR mRNA to target these malignancies. Eligible patients will receive multiple intravenous injections of ZZSW-01, which generates CAR-T cells directly in the body. The study uses a dose-escalation design to carefully monitor safety and response. Treatment is given under close medical supervision to assess how well patients tolerate the drug and to observe any early signs of benefit. Participants will undergo regular assessments including monitoring of adverse events, dose-limiting toxicities, and immune-related side effects up to 28 days after infusion. Researchers will track disease responses and survival outcomes for up to 96 weeks post-treatment. Laboratory tests will measure CAR-T cell levels and pharmacodynamics at multiple time points during the study. This thorough follow-up aims to capture both safety and early effectiveness signals over nearly two years.
CONDITIONS
Brief Title
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Research Team
H
Heng Mei, Ph.D&M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here